Founded in 2003 by Professor Chris Hancock under the name MicroOncology Ltd, Creo Medical initially focused on utilising high-frequency microwave energy and dynamic matching techniques for cancer treatment. Over time, the company's strategic vision expanded to encompass the development of medical devices with broader applications, leading to a rebranding as Creo Medical in 2010.
This evolution included the expansion of the team to incorporate expertise in the design, manufacture, production, and commercialisation of electrosurgical medical devices. In 2012, Craig Gulliford assumed the role of Chief Executive Officer, bringing with him a wealth of experience in building international businesses from their early stages to significant scales. Craig's leadership played a pivotal role in furthering Creo's evolution and strengthening its position in the industry.
As a result of these strategic initiatives, Creo Medical successfully brought to market the CROMA Advanced Energy platform. This innovative platform is powered by Kamaptive Technology and includes a comprehensive suite of multi and single modality devices, showcasing Creo's commitment to advancing medical technology.
June 2003 - MicroOncology is founded
MicroOncology is founded by Professor Chris Hancock with a vision of improving patient outcomes across indications by bringing advanced energy to therapeutic endoscopy.
MicroOncology rebrands as Creo Medical Group and the company’s focus shifts to bringing advanced energy medical devices to market.
Craig Gulliford is appointed CEO of Creo Medical Group.
Creo Medical is listed on the London Stock Exchange.
Creo Medical Moves into Chepstow HQ.
First patient treated with Speedboat Inject.
CE Mark clearance gained for Speedboat Inject and the CROMA Advanced Energy Platform.
£48.5M raised through share placings to accelerate commercialisation.
First use of Speedboat Inject in mainland Europe and South Africa.
£51.9m raised through share placings to accelerate US programme and progress research and development.
First use of Speedboat Inject in the US and India, with first commercial orders received.
MicroBlate Fine’s first in-human use.
Acquisition of Albyn Medical S.L, Boucart Medical and Endotechnik, providing Creo with established European distribution network and wider portfolio of products.
CE Mark clearance achieved for five new devices, with FDA clearance also gained for SlypSeal Flex and Microblate Fine.
US FDA clearance for MicroBlate Flex.
Opening of US HQ in Danbury.
Creo aquires Aber Electronics Limited – enhancing additional expertise to Creo and a key element of supply chain.
Launch international Pioneer Clinical Education Programme.
Long term collaboration announced with Intuitive, with heads of terms announced to grant further third-party access to Creo’s advanced energy technology.
Creo Medical opens APAC regional hub in Singapore.
First European Speedboat® UltraSlim procedure marks early commercial launch.
Our mission is to improve patient outcomes by applying Advanced Energy to the emerging field of surgical endoscopy.